Depression

How can these mHealth apps help in the treatment of depression?

How can mHealth apps help overcome barriers to access to care?

In this CME article, learn about the best ways to assess depression in the geriatric population.

Results are clinically significant for the treatment of patients with major depressive disorder.

Are lower vitamin D levels in women related to depressive mood?

Investigators have launched a 3-year study to develop predictive models that will help identify better treatment plans for patients with depression.

Coadministration of zuranolone with a standard antidepressant yields positive outcomes.

Psychiatric Times featured a wide variety of psychiatric issues and current events throughout February.

A new study showed zuranolone treatment in patients with major depressive disorder demonstrates a rapid and statistically significant reduction in depressive symptoms.

Treatment decisions lie on a continuum—befitting a dimensional approach to diagnosis.

How does treatment for self-blaming depression differ from treatment of other types of depression?

Exploring cognitive biases toward the DSM and their avoidable effects on treatment decisions.

What do these have to do with CBT, creative visualization, and contemporary psychiatry?

Associated outcomes include higher rates of psychiatric hospitalization and mortality.

Sleep, depression, and bipolar disorder: what's the connection?

Effective treatment of depression in individuals with comorbid depression and type 2 diabetes mellitus is important for both conditions.

May his words and ideals continue to inspire...

The FDA has given Investigational New Drug clearance for a clinical drug-drug interaction study of R-ketamine (PCN-101).

Here’s how to help patients see the light when faced with the winter blues.

The glass is half full: reflections on where we are and hope for where we are heading in psychiatry.

Study also suggests link between postpartum depression and insomnia.

Psychiatric Times featured a wide variety of psychiatric issues in this year’s CMEs.

Research identifies common reasons and coping mechanisms for depression that increases during the holidays.

Caplyta is now FDA-approved for depressive episodes from bipolar I and II.

Data from a clinical program evaluating the efficacy and safety of zuranolone was presented at the American College of Neuropsychopharmacology Congress. What new developments did they share?